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 2 
Cryptococcosis is a life-threatening disease often associated with HIV infection. 23 
Three Cryptococcus species CYP51 enzymes were purified and catalyzed the 14α-24 
demethylation of lanosterol, eburicol and obtusifoliol. The investigational agent 25 
VT-1129 bound tightly to all three CYP51 proteins (dissociation constant [Kd] 26 
range, 14 to 25 nM) with affinities similar to those of fluconazole, voriconazole, 27 
itraconazole, clotrimazole, and ketoconazole (Kd range, 4 to 52 nM), whereas VT-28 
1129 bound weakly to human CYP51 (Kd, 4.53 μM). VT-1129 was as effective as 29 
conventional triazole antifungal drugs at inhibiting cryptococcal CYP51 activity 30 
(50% inhibitory concentration [IC50] range, 0.14 to 0.20 μM), while it only weakly 31 
inhibited human CYP51 activity (IC50, ~600 μM). Furthermore, VT-1129 weakly 32 
inhibited human CYP2C9, CYP2C19, and CYP3A4, suggesting a low drug-drug 33 
interaction potential. Finally, the cellular mode of action for VT-1129 was 34 
confirmed to be CYP51 inhibition, resulting in the depletion of ergosterol and 35 
ergosta-7-enol and the accumulation of eburicol, obtusifolione and 36 
lanosterol/obtusifoliol in the cell membranes.  37 
 38 
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 Cryptococcosis is the most common systemic fungal infection in HIV/AIDS 40 
immunocompromised patients and is caused by the opportunistic basidiomycete yeast 41 
pathogen Cryptococcus neoformans (1) leading to infections of the lungs and brain. 42 
Meningoencephalitis is the most lethal manifestation of cryptococcosis with a life 43 
expectation of less than a month if untreated (2). Pathogenic Cryptococcus species 44 
cause disease in almost one million people annually with over 620,000 deaths and a 45 
third of all HIV/AIDS deaths are attributable to Cryptococcus species infection (1). 46 
Current treatment options are limited to a handful of drugs, namely initial induction 47 
therapy with a combination of amphotericin B and flucytosine followed by a maintenance 48 
regime of fluconazole (2). Even after administering the recommended treatment, three-49 
month mortality rates of 10 to 20% are common (3, 4). In addition, adopting such 50 
treatment is costly and often impractical (with amphotericin B requiring intravenous 51 
administration), especially in developing countries where mortality rates can approach 52 
100% (5, 6).  53 
 Three main C. neoformans varieties are observed in clinical infections. C. 54 
neoformans var. grubii (primarily serotype A), ubiquitous in the environment especially in 55 
soil, is globally distributed and is responsible for almost all cryptococcal infections in 56 
HIV/AIDS patients (6-8). C. neoformans var. neoformans (primarily serotype D) is less 57 
likely to cause severe infection and is more commonly found in Europe (4). C. 58 
neoformans var. gattii (primarily serotypes B and C), a tree-dwelling basidiomycete 59 
yeast primarily located in the tropics and sub-tropics with localized outbreaks in 60 
northeast America, is now considered a separate species (C. gattii) and is 61 
predominantly a primary pathogen infecting healthy (immunocompetent) individuals but 62 
will also infect immunocompromised patients if opportunity arises (9). Most 63 
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Cryptococcus infections of humans and nearly all infections of HIV/AIDS patients are 64 
caused by C. neoformans var. grubii, the most prevalent being the H99 strain, although 65 
C. gattii infection is increasing in prevalence, especially in North America and Africa (9). 66 
The taxonomy of Cryptococcus species is still evolving with Hagen et al (10) proposing 67 
that C. neoformans var. neoformans and C. neoformans var. grubii are separate species 68 
and that C. gattii consists of five distinct species based on phylogenetic analysis of 11 69 
genetic loci.  70 
 Azole resistance, especially towards fluconazole, amongst Cryptococcus species 71 
in the clinic can be problematic due to prolonged maintenance treatment regimens (11). 72 
Increased azole tolerance in Cryptococcus species has been attributed to point 73 
mutations in CYP51, including G484S and Y145F (12, 13), increased expression levels 74 
of CYP51 and the transporter protein AFR1 (14) and the genome plasticity of 75 
Cryptococcus species post infection (15). Recently an in silico three-dimensional model 76 
of C. neoformans CYP51 has been published (16) with the aim of aiding new drug 77 
design. Because many of the marketed azole drugs are limited by a low therapeutic 78 
index (17), a drug with a higher therapeutic index might be able to combat resistant 79 
pathogens at plasma concentrations still below toxic levels.  80 
 In this study we compared the novel tetrazole antifungal VT-1129 (18, 19) (Fig. 1) 81 
with clinical azole antifungal drugs in terms of its potency and selectivity of binding to 82 
and inhibition of three recombinant cryptococcal CYP51 enzymes compared to human 83 
CYP51, and also to human CYPs that are critical xenobiotic-metabolizing enzymes. In 84 
addition, the in vivo mode of action for VT-1129 was demonstrated through sterol profile 85 
analysis.  86 
87 
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MATERIALS AND METHODS 88 
Construction of pCWori+:CneoCYP51, pCWori+:CgruCYP51 and 89 
pCWori+:CgatCYP51 expression vectors. The C. neoformans var. neoformans CYP51 90 
gene (CneoCYP51 - UniProtKB accession number Q5KQ65), the C. neoformans var. 91 
grubii CYP51 gene (CgruCYP51 - Q09GQ2) and the C. gattii CYP51 gene (CgatCYP51 92 
- E6QZS1) were synthesized by Eurofins MWG Operon (Ebersberg, Germany) 93 
incorporating an NdeI restriction site at the 5' end and a HindIII restriction site at the 3' 94 
end of the genes cloned into the pBSIISK+ plasmid. In addition the first eight amino 95 
acids were changed to 'MALLLAVF' (20) and a four-histidine extension 96 
(CATCACCATCAC) was inserted immediately before the stop codon. The cryptococcal 97 
CYP51 genes were excised by NdeI / HindIII restriction digestion followed by cloning 98 
into the pCWori+ expression vector. Gene integrities were confirmed by DNA 99 
sequencing.  100 
 Heterologous expression and purification of recombinant cryptococcal 101 
CYP51 proteins. The pCWori+:CYP51 constructs were transformed into competent 102 
DH5α E. coli cells and expressed as previously described (21). Recombinant CYP51 103 
proteins were isolated according to the method of Arase et al (22) except that 2% 104 
(wt/vol) sodium cholate was used in the sonication buffer and Tween-20 was omitted. 105 
The solubilized CYP51 proteins were purified by affinity chromatography using Ni2+-NTA 106 
agarose as previously described (23, 21) prior to characterization. Human CYP51 with a 107 
deletion of 60 amino acids from the N-terminus (Δ60 truncated human CYP51) was 108 
expressed and purified as previously described (24) and was shown to be comparable 109 
to the full-length human CYP51 in terms of binding azole antifungal drugs. Protein 110 
purities were assessed by SDS polyacrylamide gel electrophoresis.  111 
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 Cytochrome P450 protein determinations. Reduced carbon monoxide 112 
difference spectroscopy was performed (25) with carbon monoxide being passed 113 
through the cytochrome P450 solution prior to addition of sodium dithionite to the 114 
sample cuvette (light-path 10 mm). An extinction coefficient of 91 mM-1 cm-1 (26) was 115 
used to calculate cytochrome P450 concentrations from the absorbance difference 116 
between 447 and 490 nm. Absolute spectra were determined between 700 and 300 nm 117 
(light-path 10 mm). All spectral determinations were made using a Hitachi U-3310 118 
UV/VIS spectrophotometer (San Jose, California).  119 
 Ligand binding studies. Stock 2.5 mM solutions of lanosterol, eburicol and 120 
obtusifoliol were prepared in 40% (wt/vol) (2-hydroxypropyl)--cyclodextrin (HPCD) 121 
using an ultrasonic bath. Sterol was progressively titrated against 5 μM CYP51 protein in 122 
a quartz semi-micro cuvette (light-path 4.5 mm) with equivalent amounts of 40% (wt/vol) 123 
HPCD added to the reference cuvette which also contained 5 μM CYP51. The difference 124 
in the spectrum between the absorbance at 500 and that at 350 nm was determined 125 
after each incremental addition of sterol (up to 75 μM). The sterol saturation curves were 126 
constructed from the difference spectra (difference in the A390 and A425). The substrate 127 
dissociation constants (Kds) were determined by non-linear regression (Levenberg-128 
Marquardt algorithm) using the Michaelis-Menten equation.  129 
 Studies evaluating the binding of clotrimazole, fluconazole, voriconazole, 130 
itraconazole, ketoconazole and VT-1129 to the cryptococcal CYP51 proteins were 131 
performed as previously described (27, 21) using split-cuvettes with a 4.5-mm light path. 132 
Stock 0.1-mg-ml-1 solutions of the azole antifungal drugs were prepared in dimethyl 133 
sulfoxide (DMSO) and progressively titrated against 2 μM CYP51 in 0.1 M Tris-HCl (pH 134 
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8.1) and 25% (wt/vol) glycerol. The difference spectra between 500 and 350 nm were 135 
determined after each incremental addition of azole and binding saturation curves were 136 
constructed from the difference in the absorption at the peak and the absorption at the 137 
trough (ΔApeak-trough) against the azole concentration. The properties of VT-1129 binding 138 
with 5 μM recombinant human CYP51 was also determined (24). The Kds of the 139 
enzyme-azole complex were determined by non-linear regression (Levenberg-140 
Marquardt algorithm) using a rearrangement of the Morrison equation for tight ligand 141 
binding (28, 29). Tight binding occurs where the Kd for a ligand is similar or lower than 142 
the concentration of the enzyme present (30). 143 
 CYP51 reconstitution assays. Cryptococcal CYP51 reconstitution assays (31, 144 
32) contained 0.5 μM CYP51, 1 μM Aspergillus fumigatus cytochrome P450 reductase 145 
(AfCPR1 - UniProtKB accession number Q4WM67), 50 μM C-14 methylated sterol 146 
substrate (lanosterol, eburicol, obtusifoliol), 50 μM dilaurylphosphatidylcholine, 4% 147 
(wt/vol) (2-hydroxypropyl)--cyclodextrin (HPCD), 0.4 mg ml-1 isocitrate dehydrogenase, 148 
25 mM trisodium isocitrate, 50 mM NaCl, 5 mM MgCl2 and 40 mM MOPS 149 
(morpholinepropanesulfonic acid; pH ~7.2). Assay mixtures were incubated at 37°C prior 150 
to initiation with 4 mM β-NADPHNa4 followed by shaking at 37°C for 15 minutes. Human 151 
CYP51 reconstitution assays were performed as above except 0.5 μM soluble human 152 
CYP51 (24) and 2 μM human cytochrome P450 reductase (UniProtKB accession 153 
number P16435) were used and the reaction time reduced to 5 minutes at 37°C. Sterol 154 
metabolites were recovered by extraction with ethyl acetate followed by derivatization 155 
with N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) and tetramethylsilane (TMCS) 156 
prior to analysis by gas chromatography (GC)-mass spectrometry (MS) (33).  157 
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 Determinations of the 50% inhibitory concentration (IC50s) were performed using 158 
50 μM lanosterol as substrate in which various fluconazole, itraconazole, voriconazole 159 
and VT-1129 concentrations in 2.5 μl DMSO were added prior to incubation at 37°C and 160 
addition of β-NADPHNa4.  161 
 Cryptococcus sterol analysis. C. neoformans var. neoformans (strain ATCC 162 
MYA-565), C. neoformans var. grubii (strain ATCC 208821), and C. gattii (strain ATCC 163 
MYA-4071) were grown in MOPS buffered RPMI (0.165 M MOPS), pH 7.0, at 37°C and 164 
200 rpm. MOPS buffered RPMI, pH 7.0, in the absence (1% vol/vol, DMSO control) or 165 
with fluconazole or VT-1129 was inoculated at a final concentration of 2.5 x 104 cells ml-166 
1. C. neoformans var. neoformans was grown in the presence of 0.2 μg ml-1 fluconazole 167 
or 0.0039 μg ml-1 VT-1129, C. neoformans var. grubii was grown in the presence of 0.4 168 
μg ml-1 fluconazole or 0.0039 μg ml-1 VT-1129, and C. gattii was grown in the presence 169 
of 0.4 μg ml-1 fluconazole or 0.0078 μg ml-1 VT-1129. The cultures were grown for 2 170 
days at 37°C, 200 rpm and nonsaponifiable lipids were extracted as previously reported 171 
(34). 172 
 Sterones were derivatized with methoxyamine-HCl by the addition of 200 μl of 173 
methoxyamine-HCl (2%, wt/vol, in anhydrous pyridine) and incubated for 30 min at 174 
70°C. Samples were mixed with 2 ml of saturated NaCl, and the lipids extracted in three 175 
sequential 2-ml volumes of ethyl acetate. The combined ethyl acetate fractions were 176 
washed with 2-ml volumes of NaCl-saturated 0.1 M HCl, saturated NaCl, NaCl-saturated 177 
5% (wt/vol) sodium bicarbonate solution and saturated NaCl. The samples were then 178 
dried over anhydrous magnesium sulphate and evaporated using a vacuum centrifuge. 179 
Sterols in the dried extracts were derivatized with 0.1 ml BSTFA-TMCS (99:1) and 0.3 180 
ml anhydrous pyridine (2 h at 80°C) prior to analysis by GC-MS (33). Individual sterols 181 
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and sterones were identified by reference to the retention times, mass ions, and 182 
fragmentation patterns of sterol and sterone standards. Sterol composition was 183 
calculated using peak areas. 184 
 Inhibition of human liver CYP enzymes. In vitro studies determined the IC50s of 185 
the test compounds for CYP2C9, CYP2C19, and CYP3A4 (with either midazolam or 186 
testosterone as substrates) in intact human liver microsomes. A separate series of 187 
incubation mixtures was prepared with each test compound at final concentration in 188 
reaction ranging from 0.0128 to 200 µM. Each incubation mixture contained pooled 189 
human liver microsomes at an assay concentration of 1 mg ml-1 microsomal protein (Life 190 
Technologies, Grand Island, NY) and metabolic substrates of isozymes for CYP2C9, 191 
CYP2C19, and CYP3A4 (diclofenac, omeprazole, and midazolam or testosterone, 192 
respectively) at their experimentally determined Km concentrations. Active control wells 193 
contained microsomes, a substrate(s), and the test-compound diluent (i.e. DMSO-194 
acetonitrile-phosphate buffer, 5:5:190) substituted for test compound solutions. The 195 
reaction was initiated by addition of an enzyme cofactor source (NADPH-regenerating 196 
solution; BD Biosciences, San Jose, CA) and the mixtures were incubated at 37°C. After 197 
10 min, incubation mixtures were quenched with acetonitrile, mixed, and centrifuged. 198 
The supernatant was analyzed by high-performance liquid chromatography-tandem MS 199 
for the hydroxy metabolite of the substrates. Each product peak area was normalized to 200 
be represented as a percentage of the enzyme control average. The IC50 of each test 201 
compound was determined by fitting a 4-parameter logistical fit to the dose-response 202 
data and graphically determining the inhibitor concentration at 50% of the maximal 203 
enzymatic response.  204 
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 Data analysis. All ligand binding experiments were performed in triplicate and 205 
curve-fitting of data performed using the computer program ProFit (version 6.1.12; 206 
QuantumSoft, Zurich, Switzerland). GC-MS data were analyzed using Thermo Xcalibur 207 
(version 2.2) software.  208 
 Chemicals. VT-1129 was provided by Viamet Pharmaceuticals, Inc. (Durham, 209 
USA). All other chemicals were obtained from Sigma Chemical Company (Poole, UK). 210 
Growth media, sodium ampicillin, IPTG (isopropyl-β-D-thiogalactopyranoside), and 5-211 
aminolevulenic acid were obtained from Foremedium Ltd (Hunstanton, UK). Ni2+-NTA 212 
agarose affinity chromatography matrix was obtained from Qiagen (Crawley, UK).  213 
 214 
RESULTS 215 
Expression and purification of cryptococcal CYP51 proteins. Following 216 
heterologous expression in E. coli, CneoCYP51, CgruCYP51 and CgatCYP51 were 217 
extracted by sonication with 2% (wt/vol) sodium cholate (22), which yielded 240 (±90), 218 
160 (±50) and 290 (±80) nmoles per liter culture, as determined by carbon monoxide 219 
difference spectroscopy (25). Purification by chromatography on Ni2+-NTA agarose 220 
resulted in 70%, 54% and 45% recoveries of native CneoCYP51, CgruCYP51 and 221 
CgatCYP51 proteins, respectively. SDS polyacrylamide gel electrophoresis confirmed 222 
the purity of the cryptococcal CYP51 proteins eluted on Ni2+-NTA agarose to be greater 223 
than 90% when assessed by staining intensity, with apparent molecular weights being 224 
55,000 to 58,000; the predicted molecular weights when the N-terminal modifications 225 
and the 4His C-terminal extensions are included were 62,708 for C. neoformans var. 226 
neoformans, 62,310 for C. neoformans var. grubii, and 62,689 for C. gattii.  227 
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 Spectral properties of cryptococcal CYP51 proteins. The absolute spectra of 228 
the resting oxidized forms of all three CYP51 proteins (Fig. 2A) were typical for a low-229 
spin ferric cytochrome P450 enzyme (23, 35) with α, β, Soret (γ) and δ spectral bands at 230 
566, 536, 418 and 360 nm, respectively. Reduced carbon monoxide difference spectra 231 
(Fig. 2B) gave the red-shifted heme Soret peak at 447 nm, characteristic of P450 232 
enzymes, indicating that all three CYP51 proteins were expressed in the native form.  233 
 Sterol binding properties of cryptococcal CYP51 proteins. Progressive 234 
titration with lanosterol, eburicol and obtusifoliol gave characteristic type I difference 235 
spectra for all three CYP51 proteins with a peak at 390 nm and a trough at 425 nm (Fig. 236 
3). Type I binding spectra occur when the substrate or another molecule displaces the 237 
water molecule coordinated as the sixth ligand to the low-spin hexa-coordinated heme 238 
prosthetic group, causing the heme to adopt the high-spin penta-coordinated 239 
conformation (35). The cryptococcal CYP51 proteins had similar affinities for the three 240 
sterols (Table 1) with Kd values being 16 to 18 M for lanosterol, 12 to 16 M for 241 
eburicol and 12 to 21 μM for obtusifoliol. This result suggests that all three 14α-242 
methylated sterols are potential substrates for the cryptococcal CYP51 proteins.  243 
 The sterol binding affinities of the three cryptococcal CYP51 proteins (Kd range, 244 
12 to 21 μM) were similar to those reported for other CYP51 proteins. For example, Kd 245 
values for lanosterol and eburicol were 11 to 16 and 25 to 28 μM, respectively, with 246 
Candida albicans CYP51 (21), 11 and 13 μM, respectively, with Mycosphaerella 247 
graminicola CYP51 (36); and the Kd values were 0.5 to 18 μM for lanosterol with human 248 
CYP51 (24, 37, 38). However, the sterol Kd values obtained were 10- to 20-fold higher 249 
than those obtained for lanosterol with Mycobacterium tuberculosis CYP51 (1 μM) (23) 250 
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and for lanosterol and eburicol with Trypanosoma cruzei CYP51 (1.9 and 1.2 μM, 251 
respectively) (32).  252 
 CYP51 reconstitution assays. CYP51 assays using 50 μM sterol gave turnover 253 
numbers of 1.2 to 1.9 min-1 for lanosterol, 3.7 to 7.6 min-1 for eburicol and 3.5 to 4.5 min-254 
1 for obtusifoliol (Table 1), confirming that all three cryptococcal CYP51 proteins readily 255 
catalyzed the 14α-demethylation of these three sterols. Both CneoCYP51 and 256 
CgruCYP51 displayed a substrate preference for eburicol over obtusifoliol and 257 
lanosterol, whilst CgatCYP51 displayed a substrate preference for obtusifoliol over 258 
eburicol and lanosterol. The ability of CgatCYP51, in particular, to readily demethylate 259 
obtusifoliol indicates a preference for a C-24-methylated sterol substrate.  260 
 Azole binding properties of CYP51 proteins.  All five medical azole antifungal 261 
agents and the agent being investigated, VT-1129, bound tightly to all three cryptococcal 262 
CYP51 proteins, producing type II binding spectra. The binding spectra and saturation 263 
curves obtained for fluconazole and itraconazole (Fig. 4) and for VT-1129 (Fig. 5) are 264 
shown with a peak at ~429 nm and a trough at ~412 nm. Type II binding spectra are 265 
caused by the triazole ring N-4 (fluconazole, itraconazole, and voriconazole) or the 266 
imadazole ring N-3 (clotrimazole, ketoconazole) coordinating as the sixth ligand with the 267 
heme iron (39) to form the low-spin CYP51-azole complex, resulting in a 'red-shift' of the 268 
heme Soret peak. The interaction of VT-1129 with the heme ferric ion is through a 269 
terminal (N-3 or N-4) tetrazole nitrogen atom. CneoCYP51 bound the azole antifungal 270 
agents the strongest, with apparent Kd values of 4 to 11 nM (Table 1), followed by 271 
CgatCYP51 with apparent Kd values of 5 to 24 nM, and CgruCYP51 bound the azole 272 
antifungal agents the weakest, with apparent Kd values of 14 to 52 nM. None of the 273 
cryptococcal CYP51 enzymes appeared to be inherently resistant to azole antifungal 274 
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agents, as the range of Kd values observed (4 to 52 nM) was similar to those observed 275 
with C. albicans CYP51 (10 to 56 nM) (24), whereas Aspegillus fumigatus CYP51A 276 
appeared to be inherently resistant to fluconazole with an apparent Kd value of 11.9 μM 277 
(40). The affinity of VT-1129 binding to all three cryptococcal CYP51 proteins was strong 278 
(Kd range, 11 to 25 nM) and similar to that of the other five clinical azole antifungal 279 
agents examined, suggesting VT-1129 would be effective as a therapeutic agent against 280 
Cryptococcus species infections. The similar azole binding properties of the three 281 
cryptococcal CYP51 proteins agree with their close sequence homology with 282 
CneoCYP51 sharing 98% and 96% sequence identity with CgruCYP51 and CgatCYP51, 283 
respectively.  284 
 In contrast, VT-1129 bound relatively weakly to human CYP51 (Fig. 5) with an 285 
apparent Kd of 4.53 μM (Table 1). The interaction of VT-1129 with human CYP51 was 286 
atypical, as it gave rise to a red-shifted type I difference spectrum (peak at 410 nm and 287 
trough at 426 nm) rather than the expected type II difference spectrum normally 288 
observed for the interaction of azole antifungal agents with CYP51 proteins. This 289 
suggests that the mode of interaction of VT-1129 with the human CYP51 was different 290 
from that observed with the three cryptococcal CYP51 proteins. VT-1129 still perturbs 291 
the heme environment of human CYP51, as a difference spectrum was observed, 292 
though it was not through the azole nitrogen directly coordinating with the heme ferric 293 
ion. This altered interaction of VT-1129 with human CYP51 resulted in very weak 294 
inhibition of CYP51 activity in the CYP51 reconstitution assay (see below). The Kd 295 
values obtained for VT-1129 with the cryptococcal CYP51 enzymes were 180- to 410-296 
fold lower than the Kd value obtained with the human homolog, confirming the high 297 
selectivity of VT-1129 for the fungal target enzyme. This compared favorably with the 298 
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findings for fluconazole and voriconazole, which gave Kd values that were 370- to 1,300-299 
fold and 120- to 570-fold lower, respectively, for cryptococcal CYP51 enzymes than 300 
human CYP51. VT-1129 exhibited far greater selectivity than clotrimazole, 301 
ketoconazole, and itraconazole toward cryptococcal CYP51 enzymes than toward the 302 
human homolog, with clotrimazole, ketoconazole, and itraconazole exhibiting Kd values 303 
that were only 1.3- to 15-fold lower for the fungal CYP51 than for the human CYP51.  304 
 Azole IC50 determinations. IC50 determinations (Fig. 6) confirmed that all three 305 
cryptococcal CYP51 proteins tightly bound fluconazole, itraconazole voriconazole and 306 
VT-1129, giving rise to strong inhibition of the CYP51 demethylation of lanosterol. IC50s 307 
of 0.14 to 0.20 μM (Table 1), which were obtained which were close to half the CYP51 308 
concentration present in the assay system, were obtained. VT-1129 proved equally as 309 
effective at inhibiting cryptococcal CYP51 activity as the three other azole antifungal 310 
drugs, suggesting VT-1129 would be effective at combating Cryptococcus infections. In 311 
contrast, VT-1129 only weakly inhibited human CYP51 activity (IC50, ~600 μM) (Fig. 7), 312 
in agreement with the weak perturbation of the heme environment of human CYP51 313 
observed with VT-1129 (Fig. 5), whereas clotrimazole severely inhibited human CYP51 314 
activity (IC50, 1.9 μM). The IC50s of VT-1129 observed for the cryptococcal CYP51 315 
enzymes were 3,300- to 4,000-fold lower than that obtained with the human homolog 316 
(Table 1), again confirming high selectivity for the fungal target enzyme. This was 317 
comparable to the findings for fluconazole, where the IC50s for the fungal CYP51 318 
enzymes were 6,500- to 9,000-fold lower than those for human CYP51 and with the 319 
selectivity observed with fluconazole being significantly better than that observed with 320 
voriconazole and itraconazole (Table 1). The IC50s of VT-1129 were more potent than 321 
the Kd values for binding to cryptococcal CYP51 enzymes, suggesting that the Kd values 322 
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calculated by the Morrison equation were an overestimate, in part due to the relatively 323 
high CYP51 protein concentrations required for in vitro binding studies.  324 
 Cryptococcus sterol content. The treatment of Cryptococcus spp. with 0.2 to 325 
0.4 µg ml-1 fluconazole and 0.0039 to 0.0078 µg ml-1 VT-1129 resulted in the 326 
accumulation of eburicol (Table 2), obtusifolione and lanosterol/obtusifoliol. The 327 
accumulation of CYP51 substrates is indicative of direct CYP51 inhibition in treated 328 
cells. Both azole treatments resulted in the depletion of the post-CYP51 sterol 329 
metabolites ergosta-7,22-dienol and ergosta-7-enol and the partial depletion of 330 
ergosterol levels (Table 2), showing CYP51 inhibition. In these cellular experiments, VT-331 
1129 was significantly more potent than fluconazole, as VT-1129 caused greater 332 
inhibition of cryptococcal CYP51 activity at a 50-fold lower concentration than 333 
fluconazole (relative to the results observed with the DMSO control, VT-1129 caused 334 
greater reductions in ergosterol levels than fluconazole at a 50-fold higher concentration, 335 
and in all cases, the accumulation of the 14-methylated product showed that CYP51 336 
was inhibited in cells; Table 2). 337 
 Inhibition of human liver drug-metabolizing CYPs. The inhibition of three 338 
critical xenobiotic-metabolizing CYPs by the four approved azole drugs and VT-1129 is 339 
shown in Table 3. The IC50s of the marketed agents available in the literature (41-43) 340 
agree well with those measured in this study. The imidazole-containing agent 341 
clotrimazole was the most potent CYP inhibitor, inhibiting the activities of all CYPs at 342 
sub- or low-micromolar concentrations. The three triazole-containing agents had 343 
variable inhibitory potencies, with itraconazole potently inhibiting CYP3A4 with either 344 
substrate (IC50s, 0.08 and 0.13 M), voriconazole inhibiting the activities of all CYPs with 345 
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a relatively tight range of potencies (IC50s, 4 to 13 M), and fluconazole showing a 346 
slightly broader range (IC50s, 6 to 34 M). In contrast, VT-1129 weakly inhibited the 347 
activities of each of these enzymes (IC50s, 79 to 178 M). 348 
 349 
DISCUSSION 350 
Sionov et al (14) demonstrated that C. neoformans strains are heteroresistant to 351 
fluconazole, with each strain yielding a sub-population that can survive in the presence 352 
of fluconazole concentrations well above the MIC values through disomy of 353 
chromosome 1, which duplicates the CYP51 and AFR1 transporter genes. The disomy 354 
of chromosome 1 coupled with reported G484S and Y145F CYP51 mutations (12, 13) 355 
increased CYP51 and AFR1 expression levels (14), and the genome plasticity post 356 
infection (15) may explain the divergent range of MIC values of fluconazole of 0.5 to 64 357 
μg ml-1 reported for Cryptococcus spp. (44-47). The MIC values reported for 358 
voriconazole (0.008 to 0.5 μg ml-1), itraconazole (0.015 to 0.5 μg ml-1), and 359 
posaconazole (0.008 to 0.5 μg ml-1) were lower and less variable than those reported for 360 
fluconazole (44-47), indicating the therapeutic efficacy of these triazole antifungals and 361 
their potential for use should fluconazole tolerance become problematic. However, as 362 
previously observed with Candida spp. and Aspergillus spp., it can be anticipated that 363 
tolerance against current triazole therapeutics will emerge in Cryptococcus spp.  364 
 New antifungal drug candidates for the treatment of systemic Cryptococcus 365 
infection which target CYP51 should ideally have high potency against the intended 366 
cryptococcal CYP51 target enzymes and minimal interaction with human CYP51 and 367 
other critical CYP enzymes, such as those that metabolize xenobiotics. VT-1129 meets 368 
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both these criteria by binding tightly to cryptococcal CYP51 enzymes (Kd range, 11 to 25 369 
nM) with a high affinity similar to that of other pharmaceutical azole antifungal agents (Kd 370 
range, 4 to 52 nM) while binding weakly to the CYP51 of the human host in vitro (Kd, 371 
4.53 μM). Binding studies (Fig. 4 and 5) provide useful preliminary information on a 372 
cyclized nitrogen-containing antifungal drug candidate's likely effectiveness at inhibiting 373 
CYP51 activity. However, only IC50 determinations using a CYP51 reconstitution assay 374 
system can determine the functional activity of each compound as a CYP51 inhibitor. 375 
IC50 determinations confirmed that VT-1129 is a strong inhibitor of cryptococcal CYP51 376 
activity, consistent with tight binding inhibition, but only weakly inhibits human CYP51 377 
(13% inhibition at 150 μM VT-1129). The selectivity of VT-1129 for the cryptococcal 378 
CYP51 protein over the human homolog was ~3,300-fold in terms of inhibiting CYP51 379 
catalysis, and VT-1129 was as effective as conventional triazole antifungal drugs at 380 
inhibiting cryptococcal CYP51 activity. VT-1129's selectivity for inhibiting cryptococcal 381 
CYP51 was similarly high compared to its selectivity for inhibiting key human xenobiotic-382 
metabolizing CYPs, suggesting a low potential for clinical drug-drug interactions. 383 
 Sterol profile analysis confirmed that VT-1129 inhibited cryptococcal CYP51 384 
activity in whole cells, resulting in the depletion of ergosterol and ergosta-7-enol from the 385 
cell membranes and the accumulation of the 14-methylated compounds eburicol and 386 
lanosterol/obtusifoliol and obtusifolione. In a separate study measuring a large number 387 
of Cryptococcus species isolates and using 50% inhibition as the endpoint, the MIC90 of 388 
VT-1129 was 0.060 μg ml-1 for 180 isolates of C. neoformans and 0.25 μg ml-1 for 321 389 
isolates of C. gattii (19), confirming that VT-1129 is a potent inhibitor of Cryptococcus 390 
growth. In both studies, VT-1129 was a more potent inhibitor of Cryptococcus CYP51 391 
than fluconazole. In addition, VT-1129 retains all or most of its antifungal potency 392 
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against 50 Ugandan clinical isolates of C. neoformans with elevated fluconazole MIC 393 
values (48). This potency coupled with its excellent selectivity for fungal rather than 394 
human CYP enzymes shown here supports VT-1129 as a good candidate for the 395 
treatment of systemic Cryptococcus infections. Given the unmet need for more potent 396 
drugs for the treatment of cryptococcosis, especially in sub-Saharan Africa, further 397 
assessments in clinical trials are warranted, with VT-1129 Phase 1 studies with healthy 398 
volunteers now being underway. 399 
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TABLE 1 Ligand binding affinities, azole IC50s, and turnover numbers for CYP51  587 
____________________________________________________________________________________________________________________ 
 Kd (nM) 
 _________________________________________________________________________________________________________ 
 Sterols Azoles 
 _________________________________ ______________________________________________________________________ 
CYP51 Lanosterol Eburicol Obtusifoliol Clotrimazole Fluconazole Itraconazole Ketoconazole Voriconazole VT-1129 
____________________________________________________________________________________________________________________ 
CneoCYP51 16,300 
2,800 
13,000 
1,200 
16,800 
2,100 
4 3 9 5 7 3 6 2 4 2 11 5 
CgruCYP51 17,300 
900 
11,700 
600 
12,200 
3,000 
44 18 52 15 42 11 32 15 14 9 25 4 
CgatCYP51 17,500 
1,900 
15,800 
1,300 
20,600 
1,000 
11 4 24 9 6 2 5 2 19 1 24 10 
HsapCYP51 18,400 
1,500b 
  55 5b 30,400 
4,100b 
92 7b 42 16a 2,290 120b 4,530 300 
_____________________________________________________________________________________________________________________ 
          
a HsapCYP51, Homo sapiens CYP51. 588 
b Values were taken from Warrilow et al. (24). 589 
c Thirteen percent inhibition was observed in the presence of 150 µM VT-1129. 590 
 591 
 592 
 593 
TABLE 1 (Continued) 594 
____________________________________________________________________________________________________________________ 
 IC50 (µM) Turnover no. (min-1) 
 ________________________________________________________________ _____________________________________ 
CYP51 Clotrimazole Fluconazole Itraconazole Voriconazole VT-1129 Lanosterol Eburicol Obtusifoliol 
____________________________________________________________________________________________________________________ 
CneoCYP51  0.17 0.17 0.17 0.16 1.4 0.2 6.1 0.5 3.5 0.3 
CgruCYP51  0.2 0.19 0.2 0.18 1.9 0.3 7.6 0.4 3.6 0.3 
CgatCYP51  0.14 0.16 0.16 0.15 1.2 0.2 3.7 0.4 4.5 0.6 
HsapCYP51 1.9 ~1,300b 70b 112 ~600c 22.7 4.8   
____________________________________________________________________________________________________________________ 
         
 595 
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TABLE 2 Sterol profiles of Cryptococcus spp.  597 
_________________________________________________________________________________________________ 
 Sterol composition (%) with the indicated treatment a 
 __________________________________________________________________________ 
Sterols C. neoformans var. 
neoformans 
C. neoformans var. grubii C. gattii 
 _______________________ _______________________ _______________________ 
 DMSO +FLUC +VT1129 DMSO +FLUC +VT1129 DMSO +FLUC +VT1129 
_________________________________________________________________________________________________ 
Ergosta-5,7,22,24(28)-
tetraenol 
- 1.2 ±0.3 5.0 ±0.5 2.5 ±1.4 2.1 ±1.6 2.3 ±0.3 - 1.8 ±0.2 4.8 ±1.0 
Ergosta-5,8,22-trienol - 1.0 ±0.0 3.7 ±0.3 - - - - - 3.5 ±0.2 
Ergosterol 60.6 
±2.5 
42.2 
±0.7 
11.5 
±3.9 
43.9 
±4.3 
34.1 
±3.6 
18.7 
±0.6 
49.3 
±9.7 
52.1 
±5.5 
23.2 
±2.9 
Ergosta-7,22-dienol 7.4 ±0.4 - - 9.3 ±1.1 - - 10.8 
±6.0 
- - 
Fecosterol (E8,24(28)) - - - - - - 1.0 ±0.9 - - 
Ergosta-8-enol - 1.6 ±0.4 - - - - - - 3.8 ±0.5 
Ergosta 5,7 dienol - - - - - - 3.0 ±0.6 1.8 ±0.4 - 
Ergosta-7-enol 25.3 
±1.0 
- - 28.8 
±0.5 
- - 30.2 
±6.6 
- 1.1 ±0.2 
Eburicone - - - - - - - - 1.9 ±0.3 
Lanosterol / Obtusifoliol - 3.7 ±0.9 4.4 ±0.2 1.7 ±1.1 10.9 
±2.1 
4.9 ±0.0 - 7.2 ±1.8 6.6 ±0.2 
4-methyl fecosterol - - - 2.5 ±0.4 - - - - - 
Obtusifolione - 35.9 
±1.8 
17.1 
±1.0 
- 22.1 
±1.5 
24.5 
±0.6 
- 20.0 
±6.0 
39.4 
±2.5 
Eburicol 1.5 ±0.8 12.8 
±0.7 
55.8 
±5.7 
6.8 ±2.0 30.0 
±2.1 
49.1 
±1.1 
3.1 ±2.5 13.6 
±0.7 
15.4 
±1.6 
4,4-dimethyl-ergosta-
8,24(28)-dienol 
- - - 4.0 ±0.8 - - - - - 
_________________________________________________________________________________________________ 
a Mean values from three replicates ± standard deviations are shown. FLUC, fluconazole.  598 
599 
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TABLE 3 Inhibition of human liver CYPs by fungal CYP51 inhibitors.  600 
______________________________________________________________________________________________________ 
 IC50 (μM) a 
Inhibitor _________________________________________________________________________________ 
 2C9 2C19 3A4 b 3A4 c 
______________________________________________________________________________________________________ 
Clotrimazole 1.4 (0.1) 0.6 (0.2) 0.03 (0.01) 0.045 (0.001) 
Fluconazole 34 (10) 13 (9) 32 (5) 6 (2) 
Itraconazole 80 (28) 78 (31) 0.08 (0.02) 0.13 (0.06) 
Voriconazole 10 (5) 10 (4) 13 (4) 3.8 (0.2) 
VT-1129 87 (21) 110 (80) 79 (23) 178 (31) 
______________________________________________________________________________________________________ 
     
a Values are averages of 2 to 4 separate determinations with standard deviations in parenthesizes.  601 
b Testosterone as substrate. 602 
c Midazolam as substrate.  603 
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 604 
 605 
FIG 1 Chemical structures of the azole antifungals used for IC50 studies. The chemical 606 
structures of fluconazole (molecular weight, 306), voriconazole (molecular weight, 349), 607 
VT-1129 (molecular weight, 513), and itraconazole (molecular weight, 706) are shown.   608 
 609 
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 610 
 611 
 612 
FIG 2 Absolute and reduced carbon monoxide spectra of cryptococcal CYP51 proteins. 613 
Absolute spectra in the oxidised resting state (A) and reduced carbon monoxide 614 
difference spectra (B) were determined using 5 μM solutions of purified CneoCYP51 615 
(line 1), CgruCYP51 (line 2), and CgatCYP51 (line 3). Spectral determinations were 616 
made using quartz semimicrocuvettes with a path length of 10 mm.  617 
 618 
 619 
 620 
621 
VT-1129 and cryptococcal CYP51s 
 32 
 622 
 623 
 624 
FIG 3 Sterol binding properties of cryptococcal CYP51 proteins. (A) Absorbance 625 
difference spectra were measured during the progressive titration of 5 μM CYP51 626 
proteins with lanosterol, eburicol and obtusifoliol. (B) Sterol saturation curves were 627 
constructed for lanosterol (filled circles), eburciol (hollow circles) and obtusifoliol 628 
(crosses) with the CYP51 proteins from the difference between the A390 and A425 of the 629 
type I binding spectra observed and were fitted using the Michaelis-Menten equation.  630 
 631 
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 632 
 633 
FIG 4 Azole binding properties of cryptococcal CYP51 proteins. Fluconazole and 634 
itraconazole were progressively titrated against 2 μM CneoCYP51, CgruCYP51, and 635 
CgatCYP51. (A and B) The resultant type II difference spectra obtained with fluconazole 636 
(A) and itraconazole (B) are shown. (C and D) Fluconazole (C) and itraconazole (D) 637 
saturation curves were constructed from the ΔApeak-trough of the type II binding spectra 638 
observed for CneoCYP51 (solid circles), CgruCYP51 (hollow circles), and CgatCYP51 639 
(crosses). A rearrangement of the Morrison equation was used to fit the tight ligand 640 
binding observed. All experiments were performed in triplicate, although the results of 641 
only one replicate are shown.  642 
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 645 
FIG 5 VT-1129 binding properties of cryptococcal and human CYP51 proteins. VT-1129 646 
was progressively titrated against 4 μM CneoCYP51, CgruCYP51, and CgatCYP51 and 647 
5 μM human (Homo sapiens) CYP51 (Hsap). (A) The resultant type II difference spectra 648 
obtained with the three cryptococcal CYP51 proteins and the red-shifted type I 649 
difference spectrum with human CYP51 are shown. (B) Saturation curves were 650 
VT-1129 and cryptococcal CYP51s 
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constructed from the ΔApeak-trough of the type II binding spectra observed for CneoCYP51 651 
(solid circles), CgruCYP51 (hollow circles), CgatCYP51 (crosses), and the red-shifted 652 
type I binding spectrum observed for human CYP51 (solid triangles). A rearrangement 653 
of the Morrison equation was used to fit the tight ligand binding observed. All 654 
experiments were performed in triplicate, although the results of only one replicate are 655 
shown. 656 
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 659 
FIG 6 Azole IC50 determinations for cryptococcal CYP51 proteins. The IC50s of 660 
fluconazole (A), itraconazole (B), voriconazole (C) and VT-1129 (D) for 0.5 μM 661 
CneoCYP51 (filled circles), CgruCYP51 (hollow circles) and CgatCYP51 (crosses) were 662 
determined using the CYP51 reconstitution assay with 1 μM AfCPR1 as the redox 663 
partner.  664 
665 
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 668 
FIG 7 IC50 determinations with human CYP51 for clotrimazole, voriconazole, and VT-669 
1129. The CYP51 reconstitution assay contained 0.5 μM human CYP51 and 2 μM 670 
human cytochrome P450 reductase as the redox partner in the presence of clotrimazole 671 
(filled circles), voriconazole (hollow circles), and VT-1129 (crosses) at concentrations 672 
ranging from 0 to 150 μM.  673 
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